PTGX – protagonist therapeutics, inc. (US:NASDAQ)
Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? [Yahoo! Finance]
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success [Yahoo! Finance]
J&J and Protagonist's icotrokinra scores in Phase IIb UC study [Yahoo! Finance]
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at Truist Financial Co. from $60.00 to $76.00. They now have a "buy" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com